The purpose of this study is to determine the safety and the maximal tolerated dose of
Oxaloacetate (OAA) in patients with Amyotrophic Lateral Sclerosis (ALS).
Phase:
Phase 1
Details
Lead Sponsor:
Omar Jawdat
Collaborators:
Clinical Research in ALS and Related Disorders for Therapeutic Development Rare Diseases Clinical Research Network Terra Biological LLC